Arvaya Healthcare Limited proposes Rights Issue of Equity Shares up to ₹210 Cr
Bijoy Hans · Commercial Services & Supplies
Key highlights
- Board approved Draft Letter of Offer for Rights Issue up to ₹210 crore on Nov 4, 2026
- Rights Issue to partly paid-up equity shares, final terms to be decided by Board/Committee
- Postal ballot with remote e-voting approved; NSDL appointed e-voting provider, CS Chinmay Lele as Scrutinizer
Why it's rated notable: the amount is 37% of market value (20% to 50%)
Original filing
Board Meeting Outcome for Board Meeting Outcome For The Meeting Dated 4Th November 2026 Held Through Through Video Conferencing/Other Audio-Visual Means
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Bijoy Hans
- Acquisition / mergerNotableArvaya Healthcare Limited completes acquisition of 100% equity of SIGPL
Other fundraise / allotment filings this fortnight
- Max Estates Ltd approves subsidiary incorporation, reviews Q2 2026 monitoring reports
- Cubex Tubings Ltd announces ₹75 crore preferential issue of 50 lakh convertible warrants
- Raymond Realty Allots 66.57 Lakh Convertible Warrants to J K Investors on Nov 4, 2026
- Alstone Textiles allocates ₹300 crore 2% Non-Convertible Preference Shares
- Pajson Agro India Ltd approves ESOS 2026 and plans acquisition via share swap
- Kaya Limited reports preferential allotment by Plutus Investments India Pvt Ltd
Potential multibaggers · Q2 FY27
Potential multibaggers in Commercial Services & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.